Enzo Biochem (NYSE:ENZ) Stock Price Passes Above 200-Day Moving Average of $2.70

ETFS

Enzo Biochem, Inc. (NYSE:ENZGet Rating) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.70 and traded as high as $2.74. Enzo Biochem shares last traded at $2.73, with a volume of 36,631 shares traded.

Analyst Ratings Changes

ENZ has been the subject of several recent research reports. StockNews.com initiated coverage on shares of Enzo Biochem in a research note on Tuesday. They issued a “hold” rating for the company. TheStreet downgraded shares of Enzo Biochem from a “c-” rating to a “d+” rating in a research note on Tuesday, May 17th.


Enzo Biochem Trading Up 2.2 %

The firm’s 50 day moving average is $2.35 and its 200 day moving average is $2.70. The company has a market cap of $133.01 million, a PE ratio of -21.00 and a beta of 0.88. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.52 and a quick ratio of 1.92.

Enzo Biochem (NYSE:ENZGet Rating) last issued its quarterly earnings data on Thursday, June 9th. The medical research company reported ($0.09) EPS for the quarter. The firm had revenue of $26.22 million for the quarter. Enzo Biochem had a negative net margin of 5.88% and a negative return on equity of 1.98%.

Insider Activity at Enzo Biochem

In related news, Director Bradley Louis Radoff purchased 120,000 shares of the business’s stock in a transaction on Tuesday, July 5th. The stock was acquired at an average price of $2.20 per share, with a total value of $264,000.00. Following the purchase, the director now directly owns 4,182,163 shares in the company, valued at $9,200,758.60. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders bought 193,100 shares of company stock valued at $426,524. Corporate insiders own 17.40% of the company’s stock.

Hedge Funds Weigh In On Enzo Biochem

A number of hedge funds and other institutional investors have recently bought and sold shares of ENZ. Dimensional Fund Advisors LP lifted its holdings in shares of Enzo Biochem by 2.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,596,839 shares of the medical research company’s stock worth $5,126,000 after acquiring an additional 42,690 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Enzo Biochem by 0.5% in the 1st quarter. BlackRock Inc. now owns 1,540,591 shares of the medical research company’s stock worth $4,468,000 after acquiring an additional 7,420 shares during the last quarter. Fuller & Thaler Asset Management Inc. raised its holdings in Enzo Biochem by 0.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 951,235 shares of the medical research company’s stock valued at $2,759,000 after buying an additional 4,950 shares during the last quarter. Potomac Capital Management Inc. raised its holdings in Enzo Biochem by 12.6% during the 2nd quarter. Potomac Capital Management Inc. now owns 559,500 shares of the medical research company’s stock valued at $1,158,000 after buying an additional 62,695 shares during the last quarter. Finally, Paradigm Financial Partners LLC raised its holdings in Enzo Biochem by 600.0% during the 4th quarter. Paradigm Financial Partners LLC now owns 126,000 shares of the medical research company’s stock valued at $406,000 after buying an additional 108,000 shares during the last quarter. Hedge funds and other institutional investors own 59.64% of the company’s stock.

Enzo Biochem Company Profile

(Get Rating)

Enzo Biochem, Inc, an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Enzo Biochem Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Enzo Biochem and related companies with MarketBeat.com’s FREE daily email newsletter.




Products You May Like